These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27036030)

  • 1. MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
    Lassalle S; Zangari J; Popa A; Ilie M; Hofman V; Long E; Patey M; Tissier F; Belléannée G; Trouette H; Catargi B; Peyrottes I; Sadoul JL; Bordone O; Bonnetaud C; Butori C; Bozec A; Guevara N; Santini J; Hénaoui IS; Lemaire G; Blanck O; Vielh P; Barbry P; Mari B; Brest P; Hofman P
    Oncotarget; 2016 May; 7(21):30461-78. PubMed ID: 27036030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
    Romeo P; Colombo C; Granata R; Calareso G; Gualeni AV; Dugo M; De Cecco L; Rizzetti MG; Zanframundo A; Aiello A; Carcangiu ML; Gloghini A; Ferrero S; Licitra L; Greco A; Fugazzola L; Locati LD; Borrello MG
    Endocr Relat Cancer; 2018 Mar; 25(3):217-231. PubMed ID: 29298817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two GEO MicroRNA Expression Profile Based High-Throughput Screen to Identify MicroRNA-31-3p Regulating Growth of Medullary Thyroid Carcinoma Cell by Targeting RASA2.
    Jiang M; Shi X; Zhu H; Wei W; Li J
    Med Sci Monit; 2019 Jul; 25():5170-5180. PubMed ID: 31298226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAP confers resistance to vandetanib in medullary thyroid cancer.
    Wang H; Tang J; Su Z
    Biochem Cell Biol; 2020 Jun; 98(3):443-448. PubMed ID: 32449862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC.
    Shabani N; Razaviyan J; Paryan M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
    Hum Pathol; 2018 Sep; 79():212-221. PubMed ID: 29885402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Wu PK; Park JI
    Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A miRNA signature associated with human metastatic medullary thyroid carcinoma.
    Santarpia L; Calin GA; Adam L; Ye L; Fusco A; Giunti S; Thaller C; Paladini L; Zhang X; Jimenez C; Trimarchi F; El-Naggar AK; Gagel RF
    Endocr Relat Cancer; 2013 Dec; 20(6):809-23. PubMed ID: 24127332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulated miR-9-3p Promotes Cell Growth and Inhibits Apoptosis in Medullary Thyroid Carcinoma by Targeting BLCAP.
    Chen Y; Zhang S; Zhao R; Zhao Q; Zhang T
    Oncol Res; 2017 Sep; 25(8):1215-1222. PubMed ID: 27938505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
    Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
    Chu YH; Hardin H; Schneider DF; Chen H; Lloyd RV
    Exp Mol Pathol; 2017 Oct; 103(2):229-236. PubMed ID: 29107050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
    Chu YH; Lloyd RV
    Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma.
    Szczyrba J; Nolte E; Wach S; Kremmer E; Stöhr R; Hartmann A; Wieland W; Wullich B; Grässer FA
    Mol Cancer Res; 2011 Jun; 9(6):791-800. PubMed ID: 21593139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of miRNAs as diagnostic and prognostic biomarkers, and possible therapeutic targets in medullary thyroid cancers.
    Mondin A; Bertazza L; Barollo S; Pedron MC; Manso J; Piva I; Basso D; Merante Boschin I; Iacobone M; Pezzani R; Mian C; Censi S
    Front Endocrinol (Lausanne); 2023; 14():1151583. PubMed ID: 37361540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in
    Mancikova V; Montero-Conde C; Perales-Paton J; Fernandez A; Santacana M; Jodkowska K; Inglada-Pérez L; Castelblanco E; Borrego S; Encinas M; Matias-Guiu X; Fraga M; Robledo M
    Clin Cancer Res; 2017 Mar; 23(5):1334-1345. PubMed ID: 27620278
    [No Abstract]   [Full Text] [Related]  

  • 16. MicroRNA-21 promotes proliferation, migration, and invasion of colorectal cancer, and tumor growth associated with down-regulation of sec23a expression.
    Li C; Zhao L; Chen Y; He T; Chen X; Mao J; Li C; Lyu J; Meng QH
    BMC Cancer; 2016 Aug; 16():605. PubMed ID: 27495250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
    Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
    Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
    [No Abstract]   [Full Text] [Related]  

  • 18. circPVT1 regulates medullary thyroid cancer growth and metastasis by targeting miR-455-5p to activate CXCL12/CXCR4 signaling.
    Zheng X; Rui S; Wang XF; Zou XH; Gong YP; Li ZH
    J Exp Clin Cancer Res; 2021 May; 40(1):157. PubMed ID: 33962657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of
    Pishkari S; Hadavi R; Koochaki A; Razaviyan J; Paryan M; Hashemi M; Mohammadi-Yeganeh S
    Horm Mol Biol Clin Investig; 2021 Mar; 42(3):265-271. PubMed ID: 33769725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.